JP2007045829A5 - - Google Patents

Download PDF

Info

Publication number
JP2007045829A5
JP2007045829A5 JP2006229517A JP2006229517A JP2007045829A5 JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5 JP 2006229517 A JP2006229517 A JP 2006229517A JP 2006229517 A JP2006229517 A JP 2006229517A JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5
Authority
JP
Japan
Prior art keywords
igfbp
amino acid
binding agent
specific binding
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006229517A
Other languages
English (en)
Other versions
JP4467549B2 (ja
JP2007045829A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007045829A publication Critical patent/JP2007045829A/ja
Publication of JP2007045829A5 publication Critical patent/JP2007045829A5/ja
Application granted granted Critical
Publication of JP4467549B2 publication Critical patent/JP4467549B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (9)

  1. 天然配列ヒトＩＧＦ-Ｉの位置３、５、７、１０、１４、２５、４３又は４９のアミノ酸がアラニン残基で置換されたＩＧＦ-Ｉ変異体を含む、ＩＧＦＢＰ−３特異的結合剤。
  2. 前記位置３のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  3. 前記位置５のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  4. 前記位置７のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  5. 前記位置１０のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  6. 前記位置１４のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  7. 前記位置２５のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  8. 前記位置４３のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
  9. 前記位置４９のアミノ酸が置換された請求項１に記載のＩＧＦＢＰ−３特異的結合剤。
JP2006229517A 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体 Expired - Lifetime JP4467549B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005038688A Division JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Publications (3)

Publication Number Publication Date
JP2007045829A JP2007045829A (ja) 2007-02-22
JP2007045829A5 true JP2007045829A5 (ja) 2007-04-05
JP4467549B2 JP4467549B2 (ja) 2010-05-26

Family

ID=22358799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2006229517A Expired - Lifetime JP4467549B2 (ja) 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Country Status (12)

Country Link
US (6) US6509443B1 (ja)
EP (1) EP1141015B1 (ja)
JP (3) JP2002535967A (ja)
AU (1) AU762047B2 (ja)
CA (1) CA2356257C (ja)
CY (1) CY1109452T1 (ja)
DE (1) DE60042550D1 (ja)
DK (1) DK1141015T3 (ja)
ES (1) ES2329220T3 (ja)
IL (3) IL143834A0 (ja)
PT (1) PT1141015E (ja)
WO (1) WO2000040612A1 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1141014T3 (da) * 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
JP2006504694A (ja) * 2002-09-18 2006-02-09 サントル・オスピタリエ・ドゥ・リュニヴェルシテ・ドゥ・モントリオール・（シー・エイチ・ユー・エム） Ｇｈｒｈ類似体
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
EP1841443A4 (en) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc METHOD AND SYSTEM FOR TREATING HEART ERRORS
TWI406870B (zh) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
FR2892174B1 (fr) 2005-10-14 2007-12-28 Vallourec Mannesmann Oil Gas F Element filete tubulaire muni d'un revetement protecteur sec
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
BRPI0715754A2 (pt) * 2006-08-31 2013-07-09 Hoffmann La Roche mÉtodo para a produÇço de fator do crescimento similar Á insulina i
EP2274016B1 (en) * 2008-04-03 2012-07-25 F. Hoffmann-La Roche AG Pegylated igf-i variants for use in the treatment of neuromuscular disorders
MX2010010313A (es) * 2008-04-03 2010-11-05 Hoffmann La Roche Analisis de factor de crecimiento pegilado similar a insulina.
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
CA2726230A1 (en) * 2009-07-16 2010-08-19 Arecor Limited The stabilisation of proteins
JP5571186B2 (ja) * 2009-07-22 2014-08-13 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体
MX2012002901A (es) * 2009-09-10 2012-06-27 Lonza Biologics Plc Metodo y sistema para purificacion de polipeptidos.
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
WO2011146902A1 (en) 2010-05-21 2011-11-24 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
SI2935320T1 (sl) * 2012-12-18 2019-12-31 Novartis Ag Stabilizirani polipeptidi inzulinu podobnega rastnega faktorja
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3453722A1 (en) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1987001038A1 (en) 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
EP0288451B1 (en) 1987-04-23 1994-08-10 Monsanto Company Secretion of insulin-like growth factor 1 in E. coli
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0418230B1 (en) 1988-04-12 1995-12-27 Amgen Boulder Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0597033T3 (da) 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
DK0600372T3 (da) * 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0854884A1 (en) 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
CA2276049A1 (en) 1996-12-27 1998-07-09 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2007045829A5 (ja)
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
LTPA2017029I1 (lt) Rekombinantinis FSH, įskaitant alfa 2,3- ir alfa 2,6-sialilinimą
DK2390265T3 (da) Insulinotropisk peptidderivat med modificeret N-terminal aminosyre
PE20090711A1 (es) Region constante de anticuerpo mutante
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
WO2007060117A3 (de) Chimäre keratinbindende effektorproteine
DK2035447T3 (da) Polypeptid
JP2010539123A5 (ja)
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
HK1210594A1 (en) Anti-fatigue agent comprising amino acid composition
IL184284A0 (en) Modified beta thymosin peptides
GB0503434D0 (en) Amyloid-binding peptides, analogues and uses thereof
DK1838341T3 (da) Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
FR2900332B1 (fr) Composition dentaire en deux parties.
HK1159507A1 (en) Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient
NL1031705A1 (nl) Aminozuurderivaten.
DK1971571T3 (da) Anvendelse af 3-(4-hydroxyphenyl)propionsyreamid i fremstillingen af anti-ældningssammensætninger
FR2881348B1 (fr) Composition cosmetique nettoyante sous forme solide
FR2894980B1 (fr) Compositions aqueuses epaissantes et limpides, leur utilisation dans des formulations aqueuses acides, formulations obtenues.
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
GB0704352D0 (en) "Peptide, compositions and uses thereof"
ZA201004800B (en) Compound (r)-n*6*-ethyl-6,7-dihydro-5h-indeno(5,6-d)thiazole-2,6-diamine and the use as antipsychotics
FR2897367B1 (fr) Eponge extensible en polyterephtalate, notamment pbt.
JP2012501322A5 (ja)